Swiss dermatology company Galderma has announced two European approvals for Nemluvio (nemolizumab) to treat both atopic ...

Nemluvio is now the first approved monoclonal antibody that specifically targets interleukin-31 receptor alpha ...

Galderma today announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency and Swissmedi ...

UK MHRA grants marketing approval to Galderma’s nemolizumab to treat prurigo nodularis and atopic dermatitis: United Kingdom Tuesday, February 18, 2025, 14:00 Hrs [IST] The Medi ...

These are the first approvals of nemolizumab from countries within the Access Consortium framework, with regulatory review processes ongoing in the ...

Biopharma doubles down on immunology and inflammation as companies target new pathways and seek to improve on current options ...

Switzerland’s Galderma today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic ...

Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology ...

Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU). Nemluvio is now ...

Valmet announced on December 18, 2024, that the Board of Directors of Valmet has decided to use the authorization granted by the Annual General Meeting held on March 21, 2024, to repurchase the ...

Rare Cannabinoid Company, a leader in hemp-derived wellness products, is celebrating February Sleep Awareness Month with an exclusive Buy One, Get One 50% Off sale on all CBN ...

Ad hoc announcement pursuant to Art. 53 LR This approval from the European Commission is based on robust results from the phase III OLYMPIA and ...